This website is intended for healthcare professionals only

Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Jérôme Avouac

Dear readers, It is a great pleasure to take on the role of Editor-in-Chief of touchREVIEWS in RMD, and I am grateful for the opportunity to introduce myself and to share my vision for the journal. I am a Professor of Rheumatology at Université Paris Cité and a consultant rheumatologist at Hôpital Cochin (AP-HP) in […]

Dr Elisa Pose on advancing integrated care and innovation in alcohol-related liver disease: touchIMMUNOLOGY Future Leaders 2026

Elisa Pose
3 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: May 21st 2026

We are delighted to announce Dr Elisa Pose as a touchIMMUNOLOGY Future Leader 2026, selected by peers as one of the immunologists changing the future of hepatology care.

Dr Elisa Pose is a Senior Specialist Hepatologist at Hospital Clínic Barcelona and a researcher at IDIBAPS, where her work focuses on chronic liver disease, cirrhosis, and alcohol-related liver disease. Dr Pose is also an Associate Professor of Medicine at the University of Barcelona and has contributed extensively to international liver research initiatives, including the European LIVERAIM project.

Dr Pose is recognized for her research on the diagnosis, prognosis, and treatment of liver disease, as well as for her work advancing early detection strategies and precision medicine in hepatology. She has authored numerous influential publications in the field and was recently honoured with the prestigious UEG Rising Star Award in recognition of her outstanding contributions to gastroenterology and hepatology research.

In this Q&A Dr Pose explores what first drew her pursue a career in hepatology, the most rewarding moment in her journey so far, and the most exciting current innovations in chronic liver disease.

New insights are added regularly, covering a broad range of subspecialties and evolving clinical scenarios. Sign up below for Free Access to the latest clinical updates in your specialty!


What inspired you to pursue a career in hepatology?

I was drawn to hepatology because it was a relatively under-recognized but profoundly fascinating field. The patients I encountered during my training were often very sick, with few therapeutic options and, therefore, had much to gain from any clinical or scientific advance. That asymmetry felt deeply motivating. I was also captivated by the systemic nature of liver disease: it intersects with the immune system, metabolic risk factors, alcohol use, lifestyle, mental health and social determinants, affecting multiple organs and almost every dimension of a person’s life. Hepatology offered both intellectual depth and the chance to contribute to a field where unmet needs are still vast.

What has been the most rewarding moment in your journey so far?

The most rewarding moments have been clinical ones, particularly seeing some of my first patients with advanced alcohol-related cirrhosis recompensate after achieving alcohol abstinence with the help of an integrated care pathway. Watching someone progress from decompensated cirrhosis to a stable, recompensated state, and reclaim parts of their life that seemed lost, is a powerful reminder of why we do this work, and of how much can change when alcohol use disorder is addressed alongside liver disease. Those experiences shaped my conviction that integrated, patient-centred care is the most transformative tool we have.

What current innovations in chronic liver disease excite you the most?

In alcohol-related liver disease, my main field, I am most excited by the shift toward multidisciplinary, integrated care: the closer coordination between hepatology and addiction services, the growing range of pharmacological options for alcohol use disorder usable in advanced liver disease, and the incorporation of psychological and social support into routine practice. Equally exciting is the renewed interest from the pharmaceutical industry in a previously orphan field, with several clinical trials now active in alcohol-associated hepatitis and earlier ALD stages. After decades of therapeutic stagnation, we may finally be entering an era of meaningful drug development for these patients.

More content in liver disorders.

Cite: Dr Elisa Pose on advancing integrated care and innovation in alcohol-related liver disease: touchIMMUNOLOGY Future Leaders 2026. touchIMMUNOLOGY. 21 May 2026.

Disclosures: This short article was prepared by touchIMMUNOLOGY in collaboration with Dr Pose. No fees or funding were associated with its publication.


Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup